Clinical Trials Logo

Migraine Disorders clinical trials

View clinical trials related to Migraine Disorders.

Filter by:

NCT ID: NCT03577548 Recruiting - Headache, Migraine Clinical Trials

Influence of Main Psychological and Social Factors on Primary Headaches

CEPHAPSY
Start date: May 2, 2016
Phase:
Study type: Observational

This study aims to describe the psychological and social characteristics of patients suffering from primary headache and monitored in Neurology department of Besançon University Hospital

NCT ID: NCT03576820 Recruiting - Migraine Clinical Trials

Intranasal Lidocaine to Treat Pediatric Migraine in the Emergency Department

Start date: October 15, 2018
Phase: Phase 3
Study type: Interventional

The purpose of the study is to determine the effect of intranasal lidocaine on pain score in pediatric patients with migraine. Patients with significant pain after oral analgesics and plan for intravenous (IV) abortive therapy will be asked to participate. Half of patients will be given intranasal lidocaine and the other half will be given placebo. Pain scores and associated migraine symptoms (i.e. nausea, vomiting, photophobia, phonophobia, avoidance of activities, and aura) will be monitored and compared between the groups.

NCT ID: NCT03507400 Recruiting - Migraine Clinical Trials

Introvision for Migraine and Headaches

IntroMig
Start date: September 20, 2017
Phase: N/A
Study type: Interventional

To evaluate the effect of Introvision, a mental and emotional self-regulation-technique developed by Angelika C. Wager, as migraine preventative compared to a waiting list group.

NCT ID: NCT03504150 Recruiting - Migraine Disorders Clinical Trials

Testing myWHI: Online Self-help Programs for Headaches

Start date: May 4, 2018
Phase: N/A
Study type: Interventional

This randomized controlled trial will compare the effectiveness of two online self-guided programs for youth and young adults with migraine against usual care.

NCT ID: NCT03481400 Recruiting - Migraine Clinical Trials

CGRP-induced Migraine Attacks in Patients Who Have Tried Anti-CGRP Monoclonal Antibody Treatment

Start date: July 2016
Phase: N/A
Study type: Interventional

The investigators aim to investigate the incidence of migraine attacks after calcitonin gene-related peptide (CGRP) infusion in patients who have tried anti-CGRP monoclonal antibody treatment for the prevention of migraine.

NCT ID: NCT03472092 Recruiting - Migraine Clinical Trials

Mind and Body Approaches to Pain Reduction in Youth With Migraine

Start date: October 2, 2018
Phase: Phase 2
Study type: Interventional

The overarching objective of this protocol is to identify and understand the neural and pain processing mechanisms by which youth with migraine improve in response to preventive treatment. The study design of this mechanistic investigation includes functional magnetic resonance imaging (fMRI), daily headache diaries, assessment of conditioned pain modulation via quantitative sensory testing, and validated psychometric assessments before and after the delivery of one of five treatments over an 8 week period [cognitive behavioral therapy (CBT), biofeedback-assisted relaxation training (BART) and cognitive reappraisal (CR) training, amitriptyline, and placebo]. We are examining both distinct and common pathways that may help explain the response to various preventive treatments, as well as potential predictors of outcome.

NCT ID: NCT03432286 Recruiting - Episodic Migraine Clinical Trials

A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

REBUILD-1
Start date: March 14, 2018
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.

NCT ID: NCT03418766 Recruiting - Migraine Disorders Clinical Trials

The Relationship Between Right-to-left Shunt and Brain White Matter Lesions in Patients With Migraine

CAMBRAIN
Start date: June 15, 2018
Phase:
Study type: Observational [Patient Registry]

The purpose of the study is to evaluate the prevalence of white matter lesions in Chinese migraineurs with and without right-to-left shunt. The aim is to study the relationship among right-to-left shunt, migraine and white matter lesions.

NCT ID: NCT03404336 Recruiting - Chronic Migraine Clinical Trials

Study on 30 Outpatients With Chronic Migraine Treated With Well-Being Therapy or With a Control Therapy

Start date: October 1, 2018
Phase: N/A
Study type: Interventional

Chronic migraine is a disabling type of migraine and is often resistant to treatment. Non-pharmacological interventions have been investigated as potential treatment although, unfortunately, the literature on their efficacy is poor and showed mixed results. Well-Being Therapy (WBT) is a brief psychotherapy which has shown efficacy in decreasing the relapse rates of depression in adults, in generalized anxiety disorder and in cyclothymia. It can be implemented to empower psychological well-being. The aim of the present study is to test the efficacy of WBT in a sample of patients with chronic migraine to verify if it reduces the disability due to migraine and distress, it increases the psychological well-being as well as the level of euthymia.

NCT ID: NCT03220113 Recruiting - Migraine Disorders Clinical Trials

Treatment of Chronic Migraine Headaches.

Migraine
Start date: July 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is assessment of the safety and efficacy of the De-Novo therapy in the treatment of craniofacial neuralgia and migraine headaches.This is an open-label study of simultaneous administration of combination of dexamethasone, lidocaine, and thiamine into the trigeminal nerve branches as well as greater and lesser occipital nerve bilaterally in one session. Patients who meet the exclusion and inclusion criteria are eligible for trial if they have experienced chronic migraine and craniofacial pain not responding to other prior therapies.